Abstract
AbstractPrimary glioblastoma (GBM) tumours recur following treatment. This is likely due to selection and expansion of treatment resistant cells during therapy. Details of the patterns of therapy-driven genomic evolution of these tumours are emerging, but less is known about how transcriptional profiles are altered between paired samples during treatment. The latter will reveal the gene expression signatures that are selected for during therapy and can give insights into convergent treatment resistance mechanisms. To investigate this, we have applied high-depth RNAseq to capture coding and non-coding gene expression in a preliminary set of eight pairs of primary (P) and recurrent (R) GBM from the same patient. We will discuss the results of our preliminary analyses of these data in the context of translational opportunities for inhibiting relapse-promoting clones in primary tumours.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
